Study tests new therapy for treatment-resistant hypertension

(Medical Xpress) -- Treatment-resistant hypertension affects nearly 6 million Americans and another 94 million people worldwide and is associated with increased cardiovascular risk, including stroke and heart attack, as well as heart failure and kidney disease.
To help provide patients an effective alternative for effective disease management, the Vanderbilt Heart and Vascular Institute is participating in a clinical trial to test renal denervation, a new, minimally invasive catheter-based procedure for treatment-resistant hypertension.

Patients with treatment-resistant hypertension have that remains greater than 140/90 mmHg, despite treatment with three or more antihypertensive medications.

Renal denervation uses a tiny device threaded into the renal arteries to deactivate nerves to the kidneys. Once in place, the tip of the delivers low-power, radio-frequency energy to modulate the surrounding . When overactive, these nerves can raise blood pressure and contribute to heart, kidney and blood vessel damage.

“Renal denervation and ongoing treatment with antihypertensive medications have the potential to help patients achieve their target blood pressure levels,” said Mark Robbins, M.D., assistant professor of Medicine and co-principal investigator of the trial with Jay Gainer, M.D., chief of the Vanderbilt Hypertension Center.

The clinical trial, known as SYMPLICITY HTN-3, is a randomized, controlled trial designed to evaluate the safety and effectiveness of the Symplicity Renal Denervation System and will enroll about 530 patients at more than 60 medical centers.

The Symplicity Renal Denervation System has been successfully used since 2007 to treat more than 2,000 patients worldwide and has been commercially available in Europe and Australia since 2010.

The system is not approved by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States.

“We’ve had multiple types of drugs around for the treatment of patients with refractory hypertension, but no significant improvement in care of these patients has been as effective as the results of initial Symplicity trials,” Robbins said. “What we’ve seen is a marked improvement in blood pressure management.”

“If the success of this procedure in the initial trials can be replicated in the United States, this therapy could be quite a breakthrough for a significant proportion of patients who chronically require four or more blood pressure medications to establish acceptable BP control,” Gainer said.

More information: The trial is currently enrolling patients. Contact study coordinator Sean Johnson for more information.

add to favorites email to friend print save as pdf

Related Stories

New guidelines for treating resistant hypertension

Jun 06, 2008

Resistant hypertension, blood pressure that remains above goal despite taking three antihypertensive medications or high blood pressure that is controlled but requires four or more medications to do so, may benefit from specialized ...

Recommended for you

UN Ebola czar heads to West Africa

35 minutes ago

The UN's new pointman on Ebola said Tuesday he will travel to West Africa this week to shore up health services in the four countries hit by the worst-ever outbreak of the virus.

Vietnam, Myanmar test patients for Ebola

1 hour ago

Vietnam and Myanmar are testing three patients for the deadly Ebola virus after they arrived in the Southeast Asian nations from Africa suffering fever, health officials said.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

tkjtkj
not rated yet Jun 28, 2012
Good news ..yes .. but:
is the disease defined as requiring "three or more" meds , or "Four or more". This could represent a large difference in the size of the patient population!